foravirumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458275605

| image =

| type = mab

| mab_type = mab

| source = u

| target = rabies virus glycoprotein

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 944548-38-3

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 377VY97V7S

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1743021

| C=6400 | H=9914 | N=1718 | O=1998 | S=44

}}

Foravirumab is a monoclonal antibody for the prophylaxis of rabies.[https://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], World Health Organization. It is under development by Sanofi/Crucell.{{cite book| vauthors = Khardori NM |title=Biologic Response Modifiers in Infectious Diseases, An Issue of Infectious Disease Clinics|date=2011|publisher=Elsevier Health Sciences|location=London|isbn=978-1-4557-1207-6|page=158|url=https://books.google.com/books?id=UaHQAQAAQBAJ&q=Foravirumab&pg=PT158}}